CRISPR technology has revolutionized the field of genomics by providing targeted and precise modification of genome sequences. As a robust genome-editing tool, CRISPR has attracted many basic and applied scientists and has raised hopes for curing genetic diseases. Recently, CRISPR’s potential was demonstrated as a cure for chronic hepatitis B, which is responsible for a heavy public health burden in Taiwan and China. Although promising, CRISPR is not expected to be used to treat patients anytime soon. Several technical and ethical issues remain to be solved. The presentation will use the CRISPR application in chronic hepatitis B as an example to discuss the biomedical opportunities and challenges for Taiwan in a new era of genome editing.